UBS Group’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-367,480
| Closed | -$42K | – | 8534 |
|
|
2018
Q4 | $42K | Buy |
367,480
+259,871
| +241% | +$171K | ﹤0.01% | 6261 |
|
|
2018
Q3 | $183K | Buy |
107,609
+80,869
| +302% | +$145K | ﹤0.01% | 5140 |
|
|
2018
Q2 | $47K | Sell |
26,740
-1,129,333
| -98% | -$1.95M | ﹤0.01% | 6028 |
|
|
2018
Q1 | $2.12M | Sell |
1,156,073
-1,470,904
| -56% | -$3.11M | ﹤0.01% | 3089 |
|
|
2017
Q4 | $5.86M | Sell |
2,626,977
-192,800
| -7% | -$479K | ﹤0.01% | 2198 |
|
|
2017
Q3 | $8.18M | Buy |
2,819,777
+1,674,159
| +146% | +$5.71M | ﹤0.01% | 1771 |
|
|
2017
Q2 | $5.1M | Buy |
1,145,618
+1,082,918
| +1,727% | +$4.47M | ﹤0.01% | 2131 |
|
|
2017
Q1 | $292K | Sell |
62,700
-132,593
| -68% | -$769K | ﹤0.01% | 4413 |
|
|
2016
Q4 | $1.19M | Buy |
195,293
+85,936
| +79% | +$449K | ﹤0.01% | 3403 |
|
|
2016
Q3 | $603K | Sell |
109,357
-68,004
| -38% | -$318K | ﹤0.01% | 3789 |
|
|
2016
Q2 | $674K | Buy |
177,361
+60,994
| +52% | +$207K | ﹤0.01% | 3678 |
|
|
2016
Q1 | $321K | Sell |
116,367
-195,631
| -63% | -$708K | ﹤0.01% | 4132 |
|
|
2015
Q4 | $1.77M | Buy |
311,998
+207,398
| +198% | +$1.26M | ﹤0.01% | 2902 |
|
|
2015
Q3 | $555K | Sell |
104,600
-184,281
| -64% | -$1.43M | ﹤0.01% | 3818 |
|
|
2015
Q2 | $2.4M | Buy |
288,881
+216,281
| +298% | +$1.05M | ﹤0.01% | 2804 |
|
|
2015
Q1 | $335K | Sell |
72,600
-17,980
| -20% | -$58.5K | ﹤0.01% | 4463 |
|
|
2014
Q4 | $276K | Buy |
+90,580
| New | +$268K | ﹤0.01% | 4729 |
|
Other funds holding SGYP
UBS Group's SGYP Position: Q1 2019 in Review
UBS Group sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 367,480 shares — an estimated $42K sold.
UBS Group first reported a position in SGYP in Q4 2014 and held it in 17 quarters. The position peaked at $8.18M in Q3 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.
- UBS Group reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
- UBS Group sold 367,480 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $42K.
- UBS Group first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2014 and held it in 17 quarters.
- UBS Group's Synergy Pharmaceuticals, Inc Common Stock position peaked at $8.18M in Q3 2017.
- 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.
Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.